What’s Behind the Surge in Caribou Biosciences Stock Today?
Caribou Biosciences Stock Surge: Caribou Biosciences Inc. (NASDAQ: CRBU) experienced a stock increase of 17.56% after announcing promising results from its CAR-T therapy for advanced B-cell lymphoma, showing a 64% complete response rate in patients.
ANTLER Phase 1 Trial Results: The ongoing ANTLER phase 1 trial of vispacabtagene regedleucel (vispa-cel) demonstrated an overall response rate of 82% and a one-year progression-free survival rate of 51%, confirming its efficacy compared to traditional autologous CAR-T therapies.
CB-011 Clinical Data: Caribou also reported positive results from the CaMMouflage Phase 1 trial of CB-011, an anti-BCMA CAR-T therapy for multiple myeloma, with a 92% overall response rate and 75% complete response rate, alongside a manageable safety profile.
Future Plans: The FDA has advised Caribou to conduct a randomized controlled trial for vispa-cel in specific patient populations, and the company plans to initiate a dose expansion for CB-011 by the end of the year, with data expected in 2026.
Get Free Real-Time Notifications for Any Stock
Analyst Views on CRBU
About CRBU
About the author

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, reflecting the rapid rise of precision therapies and immunotherapies, enhancing the investment outlook for companies like GT Biopharma.
- Clinical Trial Progress: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients receive a dosing of 10μg/kg/day, indicating potential efficacy in treating resistant blood cancers and providing new treatment options for patients.
- Safety Confirmation: Six patients enrolled in Cohorts 1, 2, and 3 have successfully completed GTB-3650 treatment, establishing its safety profile with no dose-limiting toxicities observed across all completed cohorts, thereby boosting confidence in the clinical trial.
- Future Outlook: GT Biopharma plans to share its next trial update in Q1 2026, with expectations to continue assessing higher doses for efficacy, further driving innovation in the field of tumor immunotherapy.

Caribou Biosciences Hosts Panel on vispa-cel to Broaden Patient Access for CAR-T Therapy
- Expert Panel Discussion: Caribou Biosciences will host a panel on December 6, 2025, to discuss how vispa-cel can promote CAR-T therapy in community hospitals, thereby expanding patient access and enhancing the company's influence in oncology treatment.
- Clinical Trial Progress: As of September 2025, 84 patients have been treated in the ANTLER trial, demonstrating that vispa-cel's safety and efficacy are comparable to autologous CAR-T therapies, which is expected to bolster the company's competitive position in the market.
- Innovative Treatment Approach: Vispa-cel is the first allogeneic CAR-T therapy in clinical use with a PD-1 knockout, aimed at improving therapeutic efficacy, potentially transforming the treatment landscape for patients with large B-cell lymphoma and increasing market appeal for the company's products.
- Regulatory Recognition: The FDA has granted vispa-cel several key designations, including Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug status, further enhancing its market potential and investment attractiveness.








